Last reviewed · How we verify
BP101
BP101 is a small molecule that targets the renin-angiotensin system to lower blood pressure.
BP101 is a small molecule that targets the renin-angiotensin system to lower blood pressure. Used for Hypertension.
At a glance
| Generic name | BP101 |
|---|---|
| Sponsor | Ivix LLX |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
BP101 works by inhibiting the angiotensin-converting enzyme (ACE), which is a key component of the renin-angiotensin system. This inhibition leads to a decrease in the levels of angiotensin II, a potent vasoconstrictor, resulting in vasodilation and a subsequent decrease in blood pressure.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- BP101 for Adults With Female Sexual Dysfunction (PHASE3)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers (PHASE1)
- Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BP101 CI brief — competitive landscape report
- BP101 updates RSS · CI watch RSS
- Ivix LLX portfolio CI